Science |
Partners and Business DevelopmentGilead places high value on partnering with companies and organizations whose strengths complement and augment our own. |
Gilead has an active research and development program to identify new and improved compounds for the treatment of HIV/AIDS, chronic hepatitis, respiratory and cardiovascular conditions, and other diseases that represent significant unmet medical needs. In 2007 alone, Gilead invested more than $590 million in research and development activities, a 55 percent increase from the year prior and an 84 percent increase over 2002. Gilead’s Research and Development Investments
Our new drug development efforts are focused on the following disease areas: |